Glassia is a plasma-derived alpha-1-proteinase inhibitor (A1-PI) listed on the Canadian Blood Services Plasma Protein and Related Products (PPRP) formulary. It is indicated for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe hereditary deficiency of A1-PI, also known as alpha-1 antitrypsin deficiency (AATD).
The Provincial Blood Coordinating Office (PBCO) has developed the following provinicial resources related to Glassia.
| Title |
Dated |
| Glassia - BC Implementation FAQ | June 2024 |
| Glassia - BC Guidance Document | August 2024 |
| Glassia - Pick-Up Authorization Letter * | June 2024 |
| Glassia - BC Patient Information (Single Sheet) * | June 2024 |
| Glassia - BC Patient Information (Foldable Pamphlet) * | June 2024 |
* Templates can be customized by Health Authorities as appropriate.
